Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inventiva S.A. American Depositary Shares (IVA) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer. Inventiva reports under the Exchange Act on Form 20-F and furnishes current information on Form 6-K, making these filings a primary source of insight into its biopharmaceutical research activities and corporate actions.
Recent Form 6-K filings referenced for Inventiva include press releases, interim financial reports, notices and documentation for Ordinary and Extraordinary General Meetings, proxy cards and voting instructions for holders of American Depositary Shares. One Form 6-K dated November 13, 2025 describes an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co. for a public offering of ADSs under a shelf registration statement on Form F-3, illustrating how the company uses SEC-registered offerings to raise capital.
On this page, users can access Inventiva’s filings as they are made available through EDGAR, including annual reports on Form 20-F and current reports on Form 6-K. These documents may cover topics such as interim financial information, shareholder meeting procedures, and legal opinions related to securities offerings. For a biopharmaceutical company focused on drug candidates acting on nuclear receptors, transcription factors and epigenetic modulation, these filings help clarify how research programs and partnerships are reflected in its regulatory reporting.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, helping readers interpret complex documents such as registration statements on Form F-3 or detailed exhibits attached to Form 6-K. Real-time updates from EDGAR, combined with simplified explanations, allow investors to review Inventiva’s regulatory history, capital-raising transactions and governance disclosures in a more accessible format.
Inventiva S.A. launched a preliminary prospectus supplement for a $125,000,000 primary offering of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under “IVA,” and the ordinary shares trade on Euronext Paris as “IVA.”
The company states it will receive the proceeds and has granted underwriters a 30‑day option to purchase additional ADSs. Intended uses include funding the NATiV3 Phase 3 MASH program, preparation/initiation of an outcomes trial, commercialization activities, and general corporate purposes.
As context, cash and cash equivalents were €97.6 million and short‑term deposits were €24.7 million as of September 30, 2025. Ordinary shares outstanding were 139,151,274 as of June 30, 2025, and 146,272,305 as of November 10, 2025. The company discloses it expects to finance activities until the end of Q3 2026 and notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern.
Inventiva S.A. announced its Ordinary and Extraordinary General Meeting, publishing the official notice on November 7, 2025. The meeting will take place on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The notice of meeting is furnished as Exhibit 99.1 to this Form 6-K and, as stated, is being furnished and not deemed filed under the Exchange Act.
Inventiva S.A. (IVA) announced proxy logistics for its upcoming shareholder meeting. The company began mailing its Proxy Card and Voting Instructions to beneficial owners of its American Depositary Shares in connection with its Ordinary and Extraordinary General Meeting to be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The materials are furnished on a Form 6-K with exhibits: 99.1 (Proxy Card) and 99.2 (Voting Instructions).
Inventiva S.A. announced its Ordinary and Extraordinary General Meeting. The meeting will be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.
The company published the notice of meeting and furnished it as Exhibit 99.1 to a Form 6-K. The Form 6-K states the information is being furnished, not filed, and that Inventiva files annual reports under cover of Form 20-F.
Inventiva S.A. submitted a Form 6-K announcing two exhibits dated October 14, 2025. The company furnished a press release as Exhibit 99.1 and made available management’s report related to previously disclosed financial statements for the six months ended June 30, 2025 as Exhibit 99.2.
Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. Exhibit 99.2 is incorporated by reference into Inventiva’s Form F-3 (File No. 333-290863) and becomes part of that registration statement from the filing date, unless later superseded.
Inventiva S.A. filed a Form 6-K as a foreign private issuer to provide investors with two key documents for the first half of 2025. The company furnished its Interim Financial Report for the six months ended June 30, 2025 as Exhibit 99.1 and a press release dated September 29, 2025 reporting unaudited first-half 2025 financial results and a corporate update as Exhibit 99.2. The filing is an information update and does not itself describe specific financial figures or major transactions.
Inventiva S.A. Schedule 13G/A reports that BioDiscovery 6 FPCI is the record holder of 12,296,295 ordinary shares, representing 8.8% of the company’s ordinary share class based on 139,151,274 shares outstanding as of May 7, 2025. Voting and dispositive authority for those shares is exercised by Andera Partners as BioDiscovery 6’s management company, and the managing partners Stephane Bergez and Francois Xavier Mauron are identified as having shared voting and dispositive power. Each Reporting Person reports 0 sole voting or dispositive power and 12,296,295 shared voting and dispositive power as of June 30, 2025.